RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:524

Li-Fraumeni syndrome

low confidenceDisorder

Publications

10,048

Trials

7

Interventional, condition-specific

Researchers

1,354

Distinct authors in sample

Gene link

TP53

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, inherited, cancer predisposition syndrome characterized by the early-onset of multiple primary cancers including breast cancer, soft tissue and bone sarcomas, brain tumors, adrenal cortical carcinoma (ACC), leukemias, and other cancers.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (8)

LFS · Li Fraumeni syndrome · Li-Fraumeni familial cancer susceptibility syndrome · Li-Fraumeni syndrome caused by mutation in TP53 · SBLA syndrome · TP53 Li-Fraumeni syndrome · TP53-related Li-Fraumeni syndrome · sarcoma, breast, leukemia and adrenal gland syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — TP53

  2. LiteraturePresent

    10,048 matched papers (5,865 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    7 matched on ClinicalTrials.gov (3 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (TP53).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

10,048

10,048 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

10,048 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

5,865 in the last 10 years · low confidence

Phrase hits: 10,048 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,354

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Kratz CP11 papers · 2026

    Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

    Papers in Europe PMC
  2. 02
    Maxwell KN10 papers · 2026

    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

    Papers in Europe PMC
  3. 03
    Hainaut P9 papers · 2026

    Institute for Advanced Biosciences, Université Grenoble Alpes, Inserm 1209, CNRS 5309, Grenoble, France.

    Papers in Europe PMC
  4. 04
    Malkin D9 papers · 2026

    Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.

    Papers in Europe PMC
  5. 05
    Bougeard G8 papers · 2026

    Univ Rouen Normandie, Inserm U1245, Normandie Univ, CHU Rouen, Department of Genetics, Rouen, France.

    Papers in Europe PMC
  6. 06
    Garber JE8 papers · 2026

    Dana-Farber Cancer Institute Boston, MA United States.

    Papers in Europe PMC
  7. 07
    Khincha PP8 papers · 2026

    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

    Papers in Europe PMC
  8. 08
    Maese LD8 papers · 2026

    Huntsman Cancer Institute Salt Lake City, UT United States.

    Papers in Europe PMC
  9. 09
    Dutzmann CM6 papers · 2026

    Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany.

    Papers in Europe PMC
  10. 10
    MacFarland SP6 papers · 2026

    Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

7

interventional trials for this specific condition

7 interventional trials matched this specific condition name; 3 currently recruiting in our sample.

Data as of 27 July 2026

7 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89.9th percentile).

low confidence · 89.9th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

7 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

15 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Li-Fraumeni syndrome" OR "Li Fraumeni syndrome" OR "Li-Fraumeni familial cancer susceptibility syndrome" OR "Li-Fraumeni syndrome caused by mutation in TP53" OR "SBLA syndrome" OR "TP53 Li-Fraumeni syndrome" OR "TP53-related Li-Fraumeni syndrome" OR "sarcoma, breast, leukemia and adrenal gland syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Li-Fraumeni syndrome" OR "Li Fraumeni syndrome" OR "Li-Fraumeni familial cancer susceptibility syndrome" OR "Li-Fraumeni syndrome caused by mutation in TP53" OR "SBLA syndrome" OR "TP53 Li-Fraumeni syndrome" OR "TP53-related Li-Fraumeni syndrome" OR "sarcoma, breast, leukemia and adrenal gland syndrome"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 7 interventional · 15 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: LFS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (10048) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T14:11:29.647Z